|
|
Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 7 (October 1), 1998:
pp. 2511-2519
Iron Release From Human Monocytes After Erythrophagocytosis In
Vitro: An Investigation in Normal Subjects and Hereditary
Hemochromatosis Patients
By
Eunice Moura,
Minke A. Noordermeer,
Nanda Verhoeven,
Andreas F.M. Verheul, and
Joannes J.M. Marx
From the Department of Internal Medicine and Eijkman-Winkler
Institute for Microbiology, Infectious Diseases and Inflammation,
University Hospital Utrecht, Utrecht, The Netherlands; and Molecular
Pathology and Immunology, Abel Salazar Institute for the Biomedical
Sciences, Porto, Portugal.
 |
ABSTRACT |
This study investigated the release of erythrocyte-derived iron from
purified human monocytes obtained from healthy volunteers and
hereditary hemochromatosis (HH) patients. After erythrophagocytosis of
59Fe-labeled erythrocytes, a complete transfer of iron from
hemoglobin (Hb) to ferritin was observed within 24 hours in both
control and HH monocytes. The iron was released from the monocytes in the form of ferritin, Hb, and as nonprotein bound low molecular weight
iron (LMW-Fe). During the initial rapid phase (<1.5 hours), iron
release mostly consisted of Hb and LMW-Fe, while in the later phase
(>1.5 hours), it was composed of ferritin and LMW-Fe. The kinetics of
iron release were identical for HH monocytes. A high percentage of the
total amount of iron was released as Hb both by viable normal and HH
monocytes, suggesting that iron release as Hb is a physiologic process,
which may occur whenever the erythrocyte-processing capacity of
macrophages is exceeded. Most remarkably, HH monocytes released twice
as much iron in a LMW form as control cells. Iron released in the form
of LMW-Fe readily binds to plasma transferrin and may contribute to the
high transferrin saturation and the occurrence of circulating
nontransferrin-bound iron observed in HH patients.
 |
INTRODUCTION |
AFTER UPTAKE by macrophages of the
mononuclear phagocytic system (MPS), red blood cells are destroyed and
iron is released from hemoglobin (Hb) to be reused for the production
of heme-, iron-sulphur-, and other proteins. Little is understood about the intracellular pathways responsible for transport of iron to the
cell surface and the form in which iron is released after erythrophagocytosis. It is known that iron storage in macrophages differs depending on the cause of iron accumulation. In secondary iron
overload, as a result of dyserythropoiesis, hemolysis, or transfusions,
macrophages are heavily loaded with iron. In contrast, in hereditary
hemochromatosis (HH), little iron is seen in the Kupffer cells and
other macrophages, while hepatocytes already suffer from iron overload.
In both forms of iron overload, low-molecular weight complexes of iron
are observed in plasma.1 Iron overload of macrophages in
secondary hemochromatosis can be explained partially by the fact that
these cells must process larger quantities of (immature) erythrocytes,
while the primary cause of iron overload in HH is an inappropriately
increased absorption of iron. However, defects in erythrophagocytosis
or differences in cellular iron processing and iron release may
contribute to the low amounts of iron in the MPS of
patients with HH.
Previous in vitro studies of human monocytes loaded with iron by
erythrophagocytosis demonstrated iron in the form of Hb and ferritin
inside the cell and in the culture supernatant, suggesting that iron
was released in these macromolecular forms.2 Studies using
rat peritoneal macrophages and Kupffer cells detected iron as ferritin
and in a low molecular weight form that readily bound to apotransferrin
or to desferrioxamine.3-5 In some of these experiments, Hb
was also recovered, but this was considered to be
artifactual.4
To investigate the normal physiology and the differences in iron
metabolism between monocytes obtained from HH patients and healthy
volunteers, monocytes were loaded with 59Fe-labeled
erythrocytes by antibody-mediated phagocytosis. Distribution of iron
within the cellular compartments and iron release was studied for a
period of 48 hours after erythrophagocytosis. Size-exclusion high
performance liquid chromatography (SE-HPLC) was used for analyzing the
forms of intracellular and released iron. Comparison of normal
monocytes with monocytes derived from patients with HH showed identical
kinetics of iron release. Both control and HH monocytes released iron
in the forms of ferritin, Hb, and as nonprotein-bound low molecular
weight iron (LMW-Fe) complexes. Iron release as Hb is probably a
physiologic process occurring whenever the erythrocyte catabolizing
capacity of macrophages is exceeded. Our previous studies demonstrated
that HH monocytes have a decreased ability to phagocytose opsonized
rabbit erythrocytes.6 Here we present evidence indicating
that after erythrophagocytosis, iron release is also different between
these two cell types. Remarkably, HH monocytes released twice as much
iron in the form of LMW-Fe complexes than control monocytes. Our
finding of increased release of LMW-Fe in HH might explain the high
transferrin saturation and nontransferrin-bound iron in HH.
 |
MATERIALS AND METHODS |
Subjects
Monocytes were obtained from healthy volunteers and from six unrelated
patients with HH. After informed consent, blood from therapeutic
phlebotomies of patients with HH (University Hospital Utrecht) was
used. Patients were characterized for HH by standard biochemical
parameters and by mutations in the HFE gene. Hb
concentration (Hb), mean corpuscular volume (MCV), serum iron (SI),
transferrin saturation (FeSat), serum ferritin concentration, alanine
amino transferase (ALAT), and -glutamyl transpeptidase ( -GT) were evaluated using routine laboratory methods. Liver biopsy and liver histology were performed in five of the six patients. For light microscopy, liver biopsies were stained with hematoxylin and with Perls' Prussian blue. HFE gene mutation was assessed as described elsewhere.7 Results for the clinical data of the patients
at the time of the experiment are shown in Table 1: two patients had
been treated by depletion of iron stores and the other four were on
intensive phlebotomy treatment. One patient, patient 1, was studied
twice during the intensive phlebotomy treatment. Intensive treatment of
HH consisted of weekly removal of 400 to 500 mL of blood until iron
stores were depleted. Iron depletion was considered to have been
achieved when the following criteria were met: (1) serum ferritin
decrease to values lower than 100 ng/mL and (2) urinary iron excretion
after 1,000 mg intramuscular desferrioxamine fell to below 20 µmol/24
hours. The total iron removed after completion of intensive treatment
is also shown in Table 1. All patients were judged clinically to have
the manifestations of homozygous HH. Genetically, four were homozygous
for the Cys282Tyr (C282Y) mutation in the HFE gene, one was
heterozygous (patient 5), and one did not carry any of the described
mutations of this gene (patient 1).
View this table:
[in this window]
[in a new window]
|
Table 1.
Clinical Data From Patients With HH at the Time of the
Experiment and Phagocytic Capacity of Monocytes as Compared With
Healthy Donors
|
|
Monocyte Isolation and Purification
Peripheral blood mononuclear cells (PBMC) were isolated from buffy
coats by fractionation on Ficoll-Paque density centrifugation at room
temperature (Ficoll-Paque, p = 1.077 g/mL; Pharmacia, Uppsala,
Sweden). Monocytes were purified from PBMC by monocyte clumping as
described by Shen et al,8 followed by adherence to plastic.
The combination of the two techniques was used to ensure a monocyte
purity higher than 85%. Monocytes were finally resuspended in RPMI
1640 (GIBCO-BRL, Breda, The Netherlands) supplemented with 5 mmol/L
HEPES, 19 mmol/L sodium bicarbonate, 10 µg/mL gentamicin and 10%
fetal bovine serum (FBS) at a concentration of 1 × 107 cells/mL, seeded on tissue culture flasks (Costar
Europe Ltd, Badhoevedorp, The Netherlands), and incubated overnight
before erythrophagocytosis. The purity of the isolated monocytes was evaluated on cytospins stained with May-Grünwald-Giemsa (Dade Diff-Quick solutions; Baxter, Düdingen, Switzerland) and by
fluorescence-activated cell sorting (FACS) analysis using
anti-CD14-fluorescein isothiocyanate (FITC)-labeled monoclonal
antibody (MoAb).
Erythrophagocytosis Assay
59Fe in vivo erythrocyte labeling.
To produce 59Fe-labeled red blood cells, 9.5 MBq
59Fe-citrate (specific activity, 0.15 to 0.44 MBq/µg
iron; Amersham, Den Bosch, The Netherlands) was injected intravenously
into a chinchilla rabbit (weight 4,000 g). A total of 6 to 19 mL of
blood was collected 1 week after injection. When required, blood could
be withdrawn every 2 weeks. To compensate for the 59Fe
decay, 59Fe-citrate was injected after each
bleeding.9
Preopsonization of the erythrocytes.
Rabbit red blood cells (RRBC) were washed four times and suspended in
RPMI at a concentration of 1 × 109
cells/mL. RRBC were incubated with heat-inactivated mouse antirabbit erythrocyte serum at a dilution of 1:2,000 at 37°C in a shaking water-bath. The mouse serum was kindly provided by Prof H. van Dijk
(Eijkman-Winkler Institute, University Hospital Utrecht, The
Netherlands). After 30 minutes, the erythrocyte suspension was washed
and resuspended in RPMI at a concentration of 1 × 109
cells/mL.
Phagocytosis.
Opsonized erythrocytes were added at a ratio of monocytes:RRBC of 1:50
for 2 hours. Noningested RRBC were removed by performing hypotonic
lysis twice. The extent of phagocytosis was evaluated by light
microscopy on Giemsa-stained cytospins. In addition, iron uptake was
assessed by counting 59Fe activity in the cells in an
automatic -counter (PW4800; Phillips, Almelo, The Netherlands).
Erythrophagocytosis was expressed as phagocytic index (PI), ie, the
number of erythrocytes taken up per monocyte. No radioactivity was
measured in the monocytes after these cells were cocultured for 24 hours with the same amount of 59Fe-Hb present in the RRBC
used in a standard erythrophagocytosis experiment. To exclude the
possibility that 59Fe-Hb detected in the supernatant was
the result of nonspecific adherence of erythrocytes to monocytes, which
were not removed by the hypotonic lysis, the following control
experiment was conducted. Monocytes and erythrocytes were incubated for
2 hours at 4°C, which prevents phagocytosis and results in
nonspecific adherence of RRBC to monocytes. Erythrocytes were then
removed by performing hypotonic lysis twice, and a standard release
experiment was conducted. No radioactivity was recovered from the
monocyte cultures. Therefore, the radioactivity measured after
erythrophagocytosis is due to uptake of RRBC and cannot be
ascribed to uptake of 59Fe-Hb from lysed erythrocytes or
from nonspecific adsorption of 59Fe-Hb or RRBC to the
monocytes.
Iron Release by Monocytes
After erythrophagocytosis, monocytes were resuspended in RPMI
supplemented with 5 mmol/L HEPES, 19 mmol/L sodium bicarbonate, and 10 µg/mL gentamicin at a concentration of 1 × 106/mL.
No protein was added. Monocytes were seeded in tissue culture flasks
(Costar Europe, Lda, Badhoevedorp, The Netherlands) and incubated at
37°C in the presence of 7% CO2 and at 95% humidity. At time points 0, 1.5, 4, 24, and 48 hours during the release experiment, cells and supernatants were collected separately and 59Fe was measured in both samples. Iron activity in the
supernatant or cell fractions is expressed as percentage of the total
iron present in the system (cells + supernatant). Erythrophagocytosis and iron release of a patient and a healthy donor were always performed
on the same day. Cell viability was determined by trypan blue dye
exclusion after each cell isolation, after erythrophagocytosis, and
during iron release. In seven experiments, cell viability was also
assessed by the 51Cr-release method.10 In
brief, monocytes were incubated with 51Cr before the
addition of nonlabeled erythrocytes. At the same time points after
erythrocyte uptake as for the release experiment, 51Cr
activity was measured in supernatants from monocytes ingesting erythrocytes and was compared with that of supernatants from monocyte cultures that were incubated with 51Cr, but were not
allowed to phagocytose erythrocytes.
Preparation of Samples for SE-HPLC
Analysis of the molecular forms in which radioactive iron was present
was performed on cell and supernatant fractions at 0, 1.5, 4, 24, and
48 hours. Cells were harvested and pelleted at 390g for 10 minutes at 4°C. Adherent cells were detached with a trypsin
solution (2 g/L trypsin/phosphate-buffered saline [PBS]) (GIBCO-BRL)
for 5 minutes at 4°C and subsequently gently removed with a cell
scraper. The supernatants were collected (S fractions) and the cell
pellets were suspended in ice-cold double-distilled deionized water
(ddH2O). Cells were lysed by three cycles of freezing ( 20°C) and thawing. Cell membranes and nuclei were pelleted
by centrifugation in the cold for 30 minutes at 10,000g (Cm
fractions). The supernatant (cell cytosol) was transferred into a
different tube (Cc fractions). Cc and S fractions were frozen
(-20°C) and subsequently dried in a speed vacuum concentration
system (Speed vacuum HS-1-110; Hetto Lab Equipment, Radiometer
Nederland, Zoetermeer, The Netherlands). 59Fe activity of
all the fractions (Cc, Cm, and S fractions) was measured. Total
activity of the samples, PI, and iron release curves were calculated
based on the radioactivity measured. The samples were then stored at
20°C until analysis was performed. Before analysis, Cc and S
fractions were reconstituted with ddH2O. One hundred
microliters of water was added per 1 × 106
cells-equivalent of dried sample. Before injection into the HPLC system, samples were filtered twice through low-protein binding 0.45 µm filters (a 0.45-µm nonsterile Spin-X from Costar, Cambridge, MA,
followed by a 0.45-µm type VI filter from Nihon Millipore Lda,
Yonezawa, Japan).
Analysis of Iron Forms by SE-HPLC
SE-HPLC was performed using an LKB high performance liquid
chromatography system consisting of a 2150 HPLC pump, a 2152 HPLC controller, and a manual Syringe Loading Sample Injector (Pharmacia LKB
Biotechnology, Uppsala, Sweden), and using a Bio-Sil Sec-250 Column
(BioRad, Hercules, CA). The fractionation range of this column for
proteins is from 10,000 to 300,000 d. Separations were performed at a
rate of 0.75 mL/min with HEPES buffer (HEPES 50 mmol/L, NaCl 100 mmol/L, NaN3 10 mmol/L, pH 7.4). The eluate was monitored
by a 2151 variable wavelength detector with absorbency detector at 280 nm and recorded on a 2210 2-channel recorder. To remove nonspecifically
bound iron, the column was finally perfused with formic acid (formic
acid 1N, pH 2.8),11 and the pH was restored with HEPES
buffer before each new fractionation. 59Fe activity was
assessed in the eluted fractions.
Preparation of Standards and Calibration of the SE-HPLC Column
To determine in which fractions ferritin, Hb, transferrin, and LMW-Fe
would elute, human liver ferritin, human 59Fe-transferrin,
rabbit 59Fe-Hb, and adenosine triphosphate
(ATP)-59Fe were prepared and injected
separately into the column. These references were prepared as described
below.
Ferritin.
Ferritin type V from human spleen was purchased from Sigma (Sigma
Chemie, Bornem, Belgium) and 2 µg ferritin was reconstituted with 200 µL H2O (final concentration 10 µg/mL). Ferritin (MW
450,000 to 600,000) was determined in the eluted fractions by a
standard method (automated chemiluminescence system-immunoluminometric assay [ILMA], on a ACS-180, from Chiron, Emeryville, CA).
59Fe-transferrin.
59Fe-labeled transferrin was prepared as follows. A
6.25-µmol/L human apotransferrin solution, (approximately 98% pure,
MW 76,000 to 81,000; Sigma Chemie) was prepared in H2O. To
a 1-mL solution, 0.1 MBq 59Fe citrate (specific activity
0.24 MBq/µg iron) was added and the iron was allowed to bind to the
apotransferrin by rotating the solution slowly at 4°C (molar ratio
Tf:Fe 1:1). To saturate the Tf binding sites, excess cold
Fe-citrate was added and the solution was further incubated overnight
at 4°C. Nonbound 59Fe was removed by gel permeation
chromatography. After fractionation, radioactivity was assessed on the
eluted fractions. Transferrin was completely saturated (Tf: Fe ratio
was 1:2).
59Fe-rabbit Hb.
Washed 59Fe-labeled RRBC (1 × 109) were
pelleted and lysed in 1 mL ice cold H2O. Membranes and
nonlysed erythrocytes were pelleted at 10,000g for 10 minutes
at 4°C. The Hb solution was filtered through a 0.45-µm filter and
an amount of Hb equivalent to 2 × 108 RRBC was
injected into the column. The Hb solution (MW ca 68,000) was freshly
prepared. Radioactivity of the collected fractions was measured.
ATP-59Fe.
ATP-59Fe complex solution was prepared as described
elsewhere.11 5 -ATP was dissolved in 0.1 mol/L
NaCl-0.1 mol/L HEPES, pH 7.0. To 10 mL ATP solution, 50 KBq
59Fe-citrate (specific activity, 0.3 MBq/µg iron) was
added. Next, a solution of cold FeCl3 in 1 mol/L HCl was
slowly added with rapid stirring and 1 mol/L NaOH was added to maintain
the pH at 7.0. The final complex had a fourfold molar excess of ATP
(5 -ATP 16 mmol/L, FeCl3 4 mmol/L). This ratio
ensures a complex free of polynuclear iron.11,12 ATP-Fe
complex solution was freshly prepared. A total of 40 µL of the
ATP-59Fe was injected into the column. Radioactivity of the
collected fractions was measured.
Calibration of the SE-HPLC column.
Ferritin eluted as a single peak (fractions 9 to 11). Transferrin was
detected as one major peak in fractions 11 to 13 and one small peak in
fractions 14 to 16, the latter probably as a result of a contamination.
Hb eluted as a single peak in fractions 13 to 15. For ATP-Fe, a single
major peak was recovered in fractions 27 to 29.
Chemical analysis of the pooled fractions.
Ferritin, transferrin, and Hb standards eluted from the HPLC column in
fractions 9 to 11, 11 to 13, and 13 to 15, respectively. Fractions from
three different release experiments were pooled, dialyzed against
ddH2O, and lyophilized. The lyophilized material was
reconstituted in H2O and analyzed for the presence of
ferritin, transferrin, Hb and iron by standard chemical
methods.13-15 Ferritin was measured by automated
chemiluminescence - ILMA; Hb was measured as free Hb by
spectrophotometry; iron was measured by dry chemistry in a Ektachem 950 from Johnson & Johnson (Clinical Diagnostics, Amersfoort, The
Netherlands); transferrin was measured by immunonephelometry in a
Hitachi 911 from Behring (Behringwerke, AG, Marburg, Germany). Ferritin
and Hb were mainly detected in those pooled fractions as predicted by
the elution patterns of the standards (ferritin, fractions 9 to 11 and
Hb, fractions 13 to 15). Iron was detected in all pooled fractions. No
transferrin was detected in any of the pooled fractions (detection
limit of the analysis method used for transferrin was 2.5 mg/L 36 nmol/L).
Measurement of Heme Oxygenase Activity in Control and HH
Monocytes
Monocytes were purified from healthy donors and from HH patients.
Because heme oxygenase activity in monocytes was too low to measure,
the following procedure was used: (1) heme oxygenase was induced in the
cells by incubation with hemin for 16 hours; (2) microsomal fractions
were isolated,; and (3) for each measurement microsomal fractions of
either six controls or six patients were pooled.16 Because
the microsomal fractions did not contain biliverdin reductase, this
enzyme was isolated from rat livers.17 As a positive
control, heme oxygenase was isolated from rat livers and
spleens.17 After induction, the viability of the cells was higher than 90%. Although the induction of heme oxygenase is complete after 6 hours,16 for convenience, it was performed
overnight. The protein concentrations in the microsomal and the
biliverdin reductase fractions were determined by the microtiter Pierce
BCA assay (Pierce, Rockford, IL).18 The
microsomal fractions of spleen, liver, and monocytes were supplemented
with the isolated liver biliverdin reductase and incubated with
hemin.19 During this incubation, the hemin is converted to
bilirubin. Samples were taken at several time intervals and the
bilirubin concentration was determined.20 In the assay,
bilirubin is converted to azopigments. The concentration of these
azopigments was determined by spectrophotometry (Bio-Rad micro plate
reader 3550, BioRad Laboratories BV, Veenendaal, The Netherlands).
Heme oxygenase activity was calculated as the amount of bilirubin
formed per 10 minutes per mg of protein in the microsomal fraction. For
this calculation the steepest part of the curve was used.
Statistical Analysis
Statistical analysis was performed using the Student's t-test
assuming equal variance for the means. Relations between phagocytic index and 51Cr release were evaluated by correlation
analysis.21 A P < .05 was considered significant.
 |
RESULTS |
Iron Release by Monocytes
After erythrophagocytosis for 2 hours, erythrocyte uptake was assessed
either by light microscopy or by measuring 59Fe. The
correlation between the two methods was highly significant (r = .92, n = 21, P < .001). HH monocytes phagocytosed less than half the number of erythrocytes taken up by healthy donor monocytes (PI
for controls = 1.3 ± 0.3 [n = 9]; PI for HH patients = 0.6 ± 0.2 [n = 10 P < .0001]). Table
1 shows the individual values of the PI for the patients. To compare
values from different experiments, the ratio of the PI from HH patients
to control performed on the same day (PId/PIp) is also shown. These
results confirm previous data of our group demonstrating a decreased
phagocytic ability of HH monocytes.6,22
Iron release was monitored at 37°C from 0 minutes up to 48 hours.
Iron release at 37°C was identical in control and HH monocytes and
displayed a biphasic pattern: a fast release phase during the first 1.5 hours, followed by a much slower release during the remainder of the
experiment (Fig 1).

View larger version (11K):
[in this window]
[in a new window]
| Fig 1.
Iron release by healthy volunteer ( ) and HH patient
( ) monocytes. After erythrophagocytosis, monocytes were incubated in
RPMI from 0 to 48 hours. At a given time point, cells and supernatants
were collected and 59Fe activity measured in both
fractions. Results are expressed as percentage of the total iron in the
system (mean ± standard deviation [SD] of six
experiments).
|
|
If uptake of erythrocytes is too high, this can influence cell
viability, thereby affecting release patterns.4 As assessed by trypan blue, cell viability of both donor and HH monocytes exceeded
90% throughout the experiments. 51Cr release experiments
gave identical results. For both normal and HH monocytes, no
significant differences in 51Cr release were found between
monocytes ingesting erythrocytes and those not doing so. There was no
difference in 51Cr release between monocytes + RRBC and control monocytes at 1.5 hours (P = .76, n = 7), at 24 hours (P = .33, n = 7), and at 48 hours (P = .32, n = 3). Furthermore, no correlation was observed between the number of
erythrocytes taken up by monocytes (PI 1.5) and 51Cr
release, demonstrating that the number of erythrocytes taken up in our
experiments was not toxic for the cells (r = .123, P = .88).
Characterization of the Intracellular Forms of Iron in Monocytes
After Erythrophagocytosis
At different time points during iron release, monocytes were lysed by
freeze-thawing and cell membranes and nuclei were removed by
centrifugation. Radioactivity present in both fractions was measured.
Most of the radioactive iron was detected in the cytosol fraction,
whereas only a low, but constant, percentage of iron was associated
with the cell membranes (Fig 2). These
results were identical for control (Fig 2A) and HH monocytes (Fig 2B).

View larger version (16K):
[in this window]
[in a new window]
| Fig 2.
Distribution of iron inside healthy volunteer (A) and HH
(B) monocytes after erythrophagocytosis and during the release
experiment. At different time points during iron release, monocytes
were lysed by freeze-thawing, and cell membranes and nuclei were
removed by centrifugation. Radioactivity was measured in the
pellet-membrane fraction ( ) and in the supernatant-cytosol fraction
( ). The total radioactivity present in the cell at any given time is
also shown ( and dashed line). Results are expressed as percentage
(mean ± SD) of total iron present in the system (= cells + supernatant) of five control and six HH experiments.
|
|
The forms in which iron was present in the cytosol fractions were
analyzed by SE-HPLC. After control monocytes had been allowed to
phagocytose for 2 hours, most of the 59Fe inside the
monocytes was present as Hb (time point 0 of release experiment)
(Fig 3). This Hb then progressively
decreased so that it was barely detectable after 24 hours. At the
beginning of the release experiment, some 59Fe could
already be detected in the form of ferritin, apparently because the
release experiment was started after 2 hours of erythrophagocytosis. In
this time period, some degradation of Hb and transfer of iron to
ferritin had already taken place. Ferritin steadily increased during
the experiment and at 24 hours, almost all of the 59Fe in
the cytosol could be identified as ferritin. Only a very low amount of
iron in the cytosol was recovered as LMW-Fe. This amount was constant
during the experiment.

View larger version (19K):
[in this window]
[in a new window]
| Fig 3.
Iron forms in the cytosol of healthy volunteer monocytes
( ) and HH monocytes ( ) after erythrophagocytosis and during the
release experiment. At different time points during iron release,
monocytes were lysed by freeze-thawing and cell membranes and nuclei
removed by centrifugation. Cytosol samples were frozen,
dried, reconstituted with bidistilled deionized water, filtered, and
fractionated on SE-HPLC. Radioactive iron was measured again in the
eluted fractions. Iron was recovered as Hb, LMW-Fe, and ferritin. The
results are expressed as percentage (mean ± SD) of the total iron
present in the system (= cells + supernatant) of five experiments.
Statistical analysis was by Student's t-test. Results of
controls and patients were not statistically different.
|
|
Identical results were obtained for HH monocytes. Although the relative
percentage of ferritin detected in the cytosol of HH monocytes was
lower at 1.5 and 4 hours, these differences between control and HH
monocytes were not statistically significant (P = .069 at 1.5 hours and P = .13 at 4 hours). In addition, the relative
percentage of ferritin in the cytosol of HH monocytes was higher at 48 hours. But again, this difference was not statistically significant
(P = .159).
Characterization of Forms of Iron Released by Control and HH
Monocytes After Erythrophagocytosis
At different time points during iron release, supernatants from control
and HH samples were collected and fractionated by SE-HPLC
(Fig 4). In the first 4 hours, most of the
activity in the supernatants was either in a LMW-form or detected as
Hb. At 24 hours and 48 hours, additional release of iron was mainly in the form of LMW-Fe and ferritin. Despite a lower rate of
erythrophagocytosis, HH monocytes released twice as much iron in a
LMW-form as compared with control cells (P < .05 at 24 hours
and P < .03 at 48 hours). When calculated as percentage of
the total 59Fe released at 24 hours, HH monocytes released
42% ± 6% of the iron as LMW-Fe, while only 16% ± 13% iron
was released in this form by control monocytes in the same period of
time. In addition, control monocytes released significantly more iron
as Hb at 24 hours (iron released as Hb was 21% ± 14% and 7.7% ± 10% for control and HH monocytes, respectively, P < .05). Significantly more iron was released as ferritin by control
monocytes at 48 hours (37.8% ± 13.6% and 24.2% ± 5.6%, for
control and HH monocytes, P < .05). No radioactive peak was
recovered at the place were the transferrin standard eluted.

View larger version (16K):
[in this window]
[in a new window]
| Fig 4.
Iron forms in the supernatants of healthy volunteer
monocytes ( ) and HH monocytes ( ) after erythrophagocytosis and
during the release experiment. At different time points during iron
release, supernatants were collected, frozen, dried, reconstituted with
ddH2O, and fractionated on SE-HPLC. Radioactive iron was
measured again in the eluted fractions. Iron was recovered as Hb,
LMW-Fe, and ferritin. The results are expressed as percentage (mean ± SD) of the total iron present in the system (= cells + supernatant)
of six experiments. Statistical analysis was by Student's
t-test ( , P < .05).
|
|
Measurement of Heme Oxygenase Activity in Control and HH
Monocytes
Control and HH monocytes released a substantial part of their iron in
the form of Hb over a 24-hour period. Because heme oxygenase is the
limiting enzyme in the breakdown of Hb and monocytes are immature
macrophages, we investigated whether this finding could be ascribed to
a lack of this enzyme in monocytes, or to the level that this enzyme
can be induced in these cells. Heme oxygenase levels are very low in
monocytes and high numbers of cells are required to detect its activity
(> 200 × 106). However, heme oxygenase
can be induced in cells by incubation with hemin. Therefore, monocytes
from controls and patients were incubated overnight with hemin and the
microsomal fractions of six controls and six patients were pooled
before measuring heme oxygenase activity. Heme oxygenase activity was
assessed by measuring bilirubin formation. As positive controls, heme
oxygenase activity of rat liver and rat spleen cells were measured as
well. Both control and HH monocytes had similar inducible heme
oxygenase activity (2.13 and 1.96 nmol bilirubin formed/10 min/mg
protein for control and HH monocytes, respectively). The heme-oxygenase activity detected was similar to the activity present in rat spleen cells (2.25 nmol bilirubin formed/10 min/mg protein).
 |
DISCUSSION |
To study iron release by monocytes and macrophages, we chose to load
monocytes with iron by erythrophagocytosis, as in vivo this method of
processing senescent erythrocytes is how the mononuclear-phagocyte system recycles most of the iron. Calculations of the rate of processing of erythrocytes in vivo suggest that, under normal conditions, splenic macrophages process one erythrocyte per macrophage per hour.23 Kondo et al4 demonstrated a strong
decrease in cell viability after 24 hours when the average number of
erythrocytes per Kupffer cell was higher than two. To resemble the in
vivo situation in our experiments, monocytes were loaded with RRBC under such conditions that as many monocytes as possible contained RRBC, but with an average number of erythrocytes per phagocyte not
exceeding 1.5.
Our experiments required viable, intact, and metabolically active
monocytes. The cell viability as assessed by trypan blue exclusion
exceeded 90% throughout the whole experiment for both donor and HH
monocytes and no significant differences were observed in the
51Cr release by monocytes ingesting erythrocytes as
compared with control monocytes. Furthermore, the progressive shift of
59Fe activity from Hb to ferritin inside the cells
demonstrates the presence of metabolically active and intact cells (Fig
3). Therefore, the experimental conditions chosen neither affected the
cell viability and metabolic activity, nor resulted in cell leakage.
As expected from erythrocyte catabolism, erythrocyte degradation
resulted in progressive transfer in the cytosol of 59Fe
from Hb to ferritin (Fig 3). In this compartment, only very little iron
was recovered as a nonprotein bound form. This might, however, be an
underestimation of the actual amount, because during the whole release
experiment, about 20% of the iron was found in the membrane fraction,
which could not be analyzed by SE-HPLC (Fig 2). In contrast to Custer
et al,2 we were not able to detect transferrin inside the
monocytes. Our results are in agreement with previous studies showing
that human macrophages, in contrast to mouse macrophages, do not
synthesize transferrin.24 The rate of iron transfer to
ferritin in the beginning of the experiment (0 to 4 hours) was
apparently slower for HH monocytes, but these differences were not
statistically significant (Fig 3). No other differences in the rate of
erythrocyte catabolism were observed between donors and patients,
suggesting that the metabolic activity of the monocytes obtained was
similar for both groups.
The erythrophagocytic ability of HH monocytes was about half that of
control monocytes, as described previously.6 Iron release
showed a biphasic pattern: an early rapid phase, followed by a slower
late phase. Although the absolute amount of iron loaded in control and
patient monocytes was different, the relative percentage of iron
released, as well as the kinetics of iron release, were identical (Fig
1). Iron release has previously been studied in vitro using rat
peritoneal macrophages performing erythrophagocytosis, rat Kupffer
cells, and human monocytes.2-4 It has also been studied in
vivo in humans.25 In all cases, similar iron release
kinetics were described and a biphasic pattern for the iron release was demonstrated. In addition, Fillet et al25 also studied iron release from the MPS in HH patients in vivo. In these patients, the
early appearance of 59Fe (fast phase) was similar to that
of healthy individuals, but in contrast to our results, the late
release phase was delayed as compared with controls.
In our study, iron released after erythrophagocytosis was recovered in
three different molecular forms: ferritin, Hb, and nonprotein-bound
LMW-Fe complexes. The fast release phase (0 to 1.5 hours) consisted
mainly of Hb and LMW-Fe. Additional release (after 1.5 hours) was
mostly in the form of ferritin and LMW-Fe (Fig 4). The most striking
finding was the observation that HH monocytes released more than twice
as much iron in the LMW form as compared with control monocytes (42%
and 16%, respectively).
Transfer of iron to ferritin after erythrophagocytosis has previously
been demonstrated in human monocytes2 and rat Kupffer cells.4 In the latter study, the addition of an
intracellular iron ligand (desferrioxamine) resulted in the binding of
iron to this chelator, suggesting the existence of a transient LMW-Fe pool inside the cell.4 In the same study, iron was found to be released as ferritin and as a form readily binding to transferrin in
the medium. Custer et al2 demonstrated iron release in the form of ferritin and transferrin, but the presence of LMW-Fe was not
studied. The detection of transferrin in these studies might be due to
the presence of serum in the media used during the release experiments.
Part of the iron released in our experiments was in the form of Hb.
This finding has been described by others previously. While Kondo et
al4 considered this finding to be a consequence of loading
the phagocytes with too many erythrocytes (number of erythrocytes per
monocyte > 2.0), Custer et al2 has postulated that this
Hb release may represent a normal physiologic process in vivo. Although
the uptake of too many erythrocytes by phagocytes is toxic and could
result in cell damage and release of Hb, our experimental conditions
ensured a phagocytic index below 1.5 and that the monocytes used in the
experiments were viable and metabolically active (see Fig 3).
Monocytes contain only limited amounts of heme oxygenase, the rate
limiting enzyme of Hb degradation.26 Because the initial release of Hb might be due to insufficient amounts of (inducible) heme
oxygenase, the presence of inducible heme oxygenase was studied in
monocytes obtained from donors and HH patients. Heme oxygenase activity
was readily induced in monocytes from both groups and in similar
amounts as the heme oxygenase activity present in rat spleen cell
suspensions. In this study, the heme oxygenase activity was measured
after overnight incubation with hemin, whereas in our experiments,
erythrophagocytosis was stopped after 2 hours. Previous studies
performed with rat peritoneal macrophages showed that the induction of
heme oxygenase was complete 5 hours after the beginning of
erythrophagocytosis.24 Iron release, however, was quite
constant in all our experiments and not only observed with monocytes,
but also with in vitro differentiated monocyte-derived macrophages.
Moreover, monocytes preincubated with low numbers of erythrocytes to
induce heme oxygenase still released similar amounts of Hb as compared
with monocytes, which were not preincubated with erythrocytes (data not
shown). Although it cannot be excluded that the early release of Hb is
in part due to the lack of heme oxygenase in the first hours of the
experiments, we feel that iron release in the form of Hb is a normal
physiologic process, not only occurring after intravascular hemolysis,
but also after normal erythrophagocytosis. Furthermore, when control
monocytes were loaded with fewer RRBC, less iron was released as Hb
(results not shown). Therefore, the differences in iron release as Hb
by control and HH monocytes may probably reflect the higher uptake of
erythrocytes by control monocytes.
An argument against the physiologic role of iron release from monocytes
as Hb may be the presence of only low concentrations of free or
haptoglobin-bound Hb in plasma (normal values < 40 mg Hb/L
plasma).27 It has been calculated that, in humans, 360 × 109 red blood cells are processed per
day.23 Assuming that all erythrocytes would be processed in
the spleen and that, like in our experiments, from all these
erythrocytes 22% of the Hb would be released into the portal system
(control monocytes at 24 hours), then the amount of Hb released would
be approximately 22 nmol/L/min. Hb or heme in the plasma will bind to
haptoglobin and to albumin or hemopexin, respectively.28
Hepatocytes possess receptors for complexed and free Hb and heme. It
has been estimated that in humans 113 to 157 nmol (21.6 to 30 mg) of
haptoglobin-Hb complexes are cleared per liter per minute
(T1/2 haptoglobin-Hb in the rat is 7 minutes).28,29 As a result, the amount of circulating Hb
will be even lower. Therefore, if Hb is released in similar amounts
from splenic macrophages as the monocytes in our studies, a maximum of
22 nmol/L/min would be released in the blood stream, which is below the
detection limit of the currently used methods of detection of free Hb
(6 µmol/L). Therefore, the release of Hb from monocytes and
macrophages is quite plausible as a mechanism of iron release from the
MPS.
The following model for iron metabolism in the MPS system can thus be
proposed. After erythrophagocytosis, Hb is degraded by heme oxygenase.
Whenever the capacity to handle erythrocytes or heme is exceeded, Hb or
heme are released into the circulation where they bind to haptoglobin,
and to hemopexin and albumin, respectively, and are taken up by
hepatocytes. In the macrophage, iron that is freed from the Hb is
either released as LMW-Fe (fast, early release phase) and binds to
circulating apotransferrin, or is incorporated into ferritin, part of
which is released during a second, slower phase. As a consequence, LMW
and transferrin-bound iron in plasma can originate directly from the
MPS, but also from hepatocytes, following further catabolism of
MPS-derived Hb. The molecular mechanisms of iron release from the MPS,
as LMW-Fe, Hb, and ferritin, remain obscure.
A hallmark of HH is the inappropriately high level of iron absorption
in the gut despite the presence of iron overload.30-32 Untreated adult HH patients, however, strongly differ in their level of
iron absorption with values ranging from around 10%, which are also
found in healthy individuals, to almost 100%31,33 (E. Moura, PhD thesis, University Utrecht, The Netherlands, 1997). All HH
patients have a high plasma iron and transferrin saturation, even in
the group with normal iron absorption. Increased iron absorption alone,
therefore, cannot explain the high transferrin iron saturation in HH
patients. Because HH monocytes release more iron in the LMW-Fe form,
this might contribute to the higher transferrin saturation and the
presence of nontransferrin-bound iron encountered in these patients.
This happens despite normal erythropoietic activity, in contrast to
severe hemolysis or dyserythropoiesis, in which patients have a very
high plasma iron turn-over and also have nontransferrin-bound iron in
their plasma.34 Another important characteristic of HH is
the absence of iron in MPS until later stages of the disease. In HH
patients, more iron is released as LMW-Fe, leading to increased
transferrin saturation and iron circulation in a LMW-form, probably as
Fe-citrate or Fe-acetate.33 LMW-Fe can then rapidly be
taken up by hepatocytes,35 explaining the preferential iron
storage in the hepatocytes.
Iron released as ferritin was also different when control and HH
monocytes were compared. At 48 hours, control monocytes released significantly more iron as ferritin (Fig 4). In a follow-up period of 2 weeks, Fillet et al25 observed a delayed late phase of iron
release in HH patients. The form of iron released in that study was not
characterized. In the present work, iron release by HH monocytes as
ferritin over a 48-hour period is lower than in control monocytes,
while the intracellular ferritin is increased. These findings suggest
that the form in which iron was released during the slower phase of
iron release, observed in HH patients by Fillet et al, may be in the
form of ferritin.
The genetic basis of HH in the majority of cases in Caucasians has been
clarified by the identification of the C282Y mutation in the HFE gene.
However, the pathogenesis of abnormal iron accumulation in HH remains
obscure. The demonstration of an increased release of LMW-Fe from HH
monocytes may represent a significant advance in the clarification of
HH pathophysiology. It may signify a basic abnormality in the retention
of iron in macrophages and probably from intestinal mucosal cells, as
well. This assumption is supported by recent work of Cairo et
al,36 who demonstrated an inappropriately high iron
regulatory protein activity in monocytes obtained from HH patients,
indicating the low levels of labile iron pool in these cells. Recently,
it was demonstrated in human embryonic kidney cells that the HFE gene
protein product associates with the transferrin receptor (TfR),
resulting in a decreased affinity of the transferrin receptor for
transferrin.37 The C282Y mutation almost completely
eliminated this association between HFE-protein and the transferrin
receptor. Iron uptake from transferrin, however, is limited in
macrophages, occurring mainly during cell diferentiation and
activation, but is latent in resident macrophages.38 We have previously reported that HH monocytes and monocyte-derived macrophages have a decreased ability to phagocytize opsonized erythrocytes (Fc receptor-mediated process), not attributable to
differential expression of Fc or complement
receptors.6,39 In addition, the level of expression of the
CD14 molecules was significantly lower in HH monocytes (unpublished
observation), which might be related to the decreased ability of HH
monocytes to produce tumor necrosis factor- (TNF- ) on stimulation
with lipopolysaccharide (LPS), as has been reported by Gordeuk et
al.40 Taken together, these observations may suggest that,
besides binding to the TfR, the HFE protein also associates with other
surface proteins, thereby promoting or stabilizing their expression on the outer-cell membrane or influencing their function.
The molecular mechanisms of iron release from the MPS, as LMW-Fe, Hb,
and ferritin remains obscure. However, the remarkable finding of the
high proportion of iron released from the monocytes, as Hb and ferritin
ought to be incorporated into models of iron metabolism and
ferrokinetics. Our finding of increased release of LMW-Fe in HH may
explain the high transferrin saturation and nontransferrin-bound iron
in HH, especially in patients with low iron absorption.
 |
FOOTNOTES |
Submitted February 9, 1998;
accepted May 26, 1998.
Supported by Grant No. BD 1656-91 from Junta Nacional de
Investigaçäo Científica e Tecnológica
(Portugal).
Address reprint requests to Joannes J.M. Marx, MD, PhD,
University Hospital Utrecht, Department of Internal
Medicine, Postnr. G02.228, PO Box 85500, 3508 GA Utrecht, The
Netherlands; e-mail: J.Marx{at}digd.azu.nl.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" is accordance with 18 U.S.C. section 1734 solely to indicate this fact.
 |
REFERENCES |
1.
Gutteridge JMC,
Rowley DA,
Griffiths E,
Halliwell B:
Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic hemochromatosis.
Clin Sci
68:463,
1985[Medline]
[Order article via Infotrieve]
2.
Custer G,
Balcerzak S,
Rinehart J:
Human macrophages hemoglobin-iron metabolism in vitro.
Am J Hematol
13:23,
1982[Medline]
[Order article via Infotrieve]
3.
Saito K,
Nishisato T,
Grasso JA,
Aisen P:
Interaction of transferrin with iron-loaded peritoneal macrophages.
Br J Haematol
62:275,
1986[Medline]
[Order article via Infotrieve]
4.
Kondo H,
Saito K,
Grasso JP,
Aisen P:
Iron metabolism in the erythrophagocytosing Kupffer cell.
Hepatology
8:32,
1988[Medline]
[Order article via Infotrieve]
5.
Sibille JC,
Kondo H,
Aisen P:
Interactions between isolated hepatocytes and Kupffer cells in iron metabolism: A possible role for ferritin as an iron carrier protein.
Hepatology
8:296,
1988[Medline]
[Order article via Infotrieve]
6.
Moura E,
Verheul AFM,
Marx JJM:
A functional defect in hereditary haemochromatosis monocytes and monocyte-derived macrophages.
Eur J Clin Invest
28:164,
1998[Medline]
[Order article via Infotrieve]
7.
Santos M,
Clevers HC,
Marx JJM:
Mutations of the hereditary haemochromatosis candidate gene HLA-H in porphyria cutanea tarda.
N Engl J Med
336:1327,
1997[Free Full Text]
8.
Shen L,
Guyre PM,
Ball ED,
Fanger MW:
Glucocorticoid enhances gamma interferon effects on human monocyte antigen expression and ADCC.
Clin Exp Immunol
65:387,
1986[Medline]
[Order article via Infotrieve]
9.
Moura E,
Verheul AFM,
Marx JJM:
Fe-labelling of rabbit erythrocytes as a continuous source for iron metabolism studies.
Lab Anim
32:284,
1998[Abstract/Free Full Text]
10.
Simon RH,
Scoggin CH,
Patterson D:
Hydrogen peroxide causes the fatal injury to human fibroblasts exposed to oxygen radicals.
J Biol Chem
256:7181,
1981[Abstract/Free Full Text]
11.
Weaver J,
Pollack S,
Zhan H:
Low molecular weight iron from guinea pig reticulocytes isolated by Sephadex G-25 chromatography.
Eur J Haematol
43:321,
1989[Medline]
[Order article via Infotrieve]
12.
Mansour AN,
Thompson C,
Theil EC,
Chasteen ND,
Sayers DE:
Fe(III)-ATP complexes. Models for ferritin and other polynuclear iron complexes with phosphate.
J Biol Chem
260:7975,
1985[Abstract/Free Full Text]
13. International Committee for Standardization in Haematology:
Recommendation for measurement of serum iron in human blood. Br J
Haematol 38:291, 1987
14. International Committee for Standardization in Haematology: The
measurement of total and unsaturated iron-binding capacity in serum. Br
J Haematol 38:281, 1987
15. Dacie Sir JV, Lewis SM: Practical Haematology. New York, NY,
Churchill Livingstone, 1985
16.
Shibahara S,
Yoshida T,
Kikuchi G:
Induction of heme oxygenase by haemin in cultured pig alveolar macrophages.
Arch Biochem Biophys
188:243,
1978[Medline]
[Order article via Infotrieve]
17.
Tenhunen R,
Ross ME,
Marver HS,
Schmid R:
Reduced nicotinamide-adenine dinucleotide phosphate dependent biliverdin reductase: Partial purification and characterization.
Biochemistry
9:298,
1970[Medline]
[Order article via Infotrieve]
18.
Sörensen K,
Brodbeck U:
A sensitive protein assay using microtiter plates.
Experientia
42:161,
1986
19.
Tenhunen R,
Marver HS,
Schmid R:
The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase.
Proc Natl Acad Sci USA
61:748,
1986
20.
Doumas BT,
Kwok-Cheung PP,
Perry BW,
Jendrzejczak B,
McComb RB,
Schaffer R,
Hause LL:
Candidate reference method for determination of total bilirubin in serum: Development and validation.
Clin Chem
31:1779,
1985[Abstract/Free Full Text]
21. Kreyszig E: Introductionary Mathematical Statistics. Principles
and Methods. New York, NY, Wiley, 1970
22.
Van Asbeck BS,
Marx JJM,
Sruyvenberg A,
Verhoef J:
Functional defects in phagocytic cells from patients with iron overload.
J Infect
8:232,
1984[Medline]
[Order article via Infotrieve]
23. Kay MMB: Recognition and removal of senescent cells, in de Sousa
M, Brock JH (eds): Iron in Immunity, Cancer and Inflammation. New York,
NY, Wiley, 1989, p 17
24.
Gemsa D,
Woo CH,
Fudenberg H,
Schmid R:
Erythrocyte catabolism by macrophages in vitro. The effect of hydrocortisone on erythrophagocytosis and on the induction of haem oxygenase.
J Clin Invest
52:812,
1973
|